Search Patents
  • Publication number: 20090081780
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 26, 2009
    Applicant: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Publication number: 20100150923
    Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.
    Type: Application
    Filed: June 13, 2006
    Publication date: June 17, 2010
    Applicant: Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
    Inventors: Chengyu Jiang, Feng Guo, Shuan Rao, Bing Guan, Yi Huan, Peng Yang
  • Publication number: 20140205621
    Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.
    Type: Application
    Filed: June 26, 2012
    Publication date: July 24, 2014
    Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
  • Patent number: 7452542
    Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: November 18, 2008
    Assignee: Vanderbilt University
    Inventor: Mark Denison
  • Patent number: 7582740
    Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3? non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: September 1, 2009
    Assignee: The Trustees of Columbia University In the City of New York
    Inventors: Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado
  • Patent number: 6867021
    Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: March 15, 2005
    Assignee: Board of Trustees of Michigan State University
    Inventors: Roger K. Maes, Annabel G. Wise
  • Patent number: 6280974
    Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: August 28, 2001
    Assignee: Pfizer Inc
    Inventors: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
  • Publication number: 20120082693
    Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.
    Type: Application
    Filed: July 20, 2011
    Publication date: April 5, 2012
    Inventors: Sylvie VAN DER WERF, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
  • Patent number: 7220852
    Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: May 22, 2007
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Suxiang Tong, Sherif R. Zaki
  • Patent number: 7618802
    Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: November 17, 2009
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
  • Publication number: 20120177675
    Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
    Type: Application
    Filed: July 5, 2010
    Publication date: July 12, 2012
    Applicant: INSTITUTE FOR ANIMAL HEALTH
    Inventors: Paul Britton, Erica Bickerton, Maria Armesto
  • Patent number: 8828407
    Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: September 9, 2014
    Assignee: The Pirbright Institute
    Inventors: Paul Britton, Erica Bickerton, Maria Armesto
  • Publication number: 20080213284
    Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
    Type: Application
    Filed: January 10, 2005
    Publication date: September 4, 2008
    Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
  • Publication number: 20090022735
    Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.
    Type: Application
    Filed: July 28, 2008
    Publication date: January 22, 2009
    Applicant: National Health Research Institutes
    Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
  • Patent number: 7320857
    Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: January 22, 2008
    Assignee: Chinese National Human Genome Center at Shanghai
    Inventors: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min
  • Publication number: 20020127245
    Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
    Type: Application
    Filed: October 5, 2001
    Publication date: September 12, 2002
    Inventors: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine Jones
  • Publication number: 20040038202
    Abstract: The present invention relates to the use of novel nucleotide sequences for the spike peptide, pol region peptide and M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.
    Type: Application
    Filed: January 30, 2003
    Publication date: February 26, 2004
    Applicant: Michigan State University
    Inventors: Roger K. Maes, Annabel G. Wise, Matti Kiupel
  • Patent number: 7255986
    Abstract: The present invention relates to the use of novel nucleotide sequences for the M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: August 14, 2007
    Assignee: The Board of Trustees Operating Michigan State University
    Inventors: Roger K. Maes, Annabel G. Wise, Matti Kiupel
  • Publication number: 20130071833
    Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
    Type: Application
    Filed: January 18, 2011
    Publication date: March 21, 2013
    Applicant: Universiteit Utrecht Holding B.V.
    Inventors: Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink
  • Patent number: 7897744
    Abstract: The invention provides, in part, the genomic sequence of a putative coronavirus, the SARS virus, and provides novel nucleic acid and amino acid sequences that may be used, for example, for the diagnosis, prophylaxis, or therapy of a variety of SARS virus related disorders.
    Type: Grant
    Filed: April 28, 2004
    Date of Patent: March 1, 2011
    Assignee: The Public Health Agency of Canada
    Inventors: Frank Plummer, Heinz Feldmann, Steven Jones, Yan Li, Nathalie Bastien, Robert Conrad Brunham, Angela Brooks-Wilson, Robert Holt, Christopher Upton, Rachel Roper, Caroline Astell, Steven Jones